-
There were 72, 129 individuals (male/female = 63.1%/36.9%) who met all conditions required for the China-PAR equation. Basic characteristics of the individuals who satisfied the calculation conditions are presented in Supplementary Table S1 (available in www.besjournal.com). The average age of the individuals was 49.8 ± 9.6 years, all lived and worked south of the Yangtze River for at least three years, and the vast majority lived in cities (96.7%).
There were more male than female smokers (35.5% vs. 0.14%). The medical history was entirely self-reported, and 9% (male/female = 11.6%/4.7%) reported having diabetes, 1.6% (male/female = 1.4%/1.9%) reported taking statins, 12.2% (male/female = 14.6%/8.2%) reported receiving antihypertensive treatment, and 5.7% (male/female = 7.5%/2.7%) reported having a family history of ASCVD.
-
The mean China-PAR 10-year CVD risks are presented in Supplementary Table S2 (available in www.besjournal.com). The mean 10-year CVD risk score of the total population was 2.89% ± 3.38%, and the risk scores of males and females were 3.82% ± 3.76% and 1.30% ± 1.65%, respectively. The mean risk scores for the three age subgroups were 0.94% ± 1.59%, 3.48% ± 3.13%, and 8.43% ± 4.39%, respectively.
The proportion of participants in each risk category based on sex is presented in Figure 1. Of the total 72, 129 individuals evaluated, 13.9% had moderate 10-year CVD risk, and 4.7% were high-risk. The proportions of intermediate-risk and high-risk individuals in the male subgroup were 20% and 7.3%, respectively, and 3.5% and 0.3% in the female subgroup.
-
The risk factor profile of the study population in each risk categorization is shown in Table 1. Among the risk factors used in the China-PAR, the average or proportion of individuals with a given risk factor tended to be higher in each subsequent risk classification, but the percentages of current smokers and those with a family history of ASCVD were not significantly different between the intermediate- and high-risk groups. Similar to the risk factors used in the China-PAR, the average value of additional risk factors evaluated outside of the equation also increased as the CVD risk level increased except for BMI and AST.
Table 1. The Value of Risk Factors in the Three 10-year ASCVD Risk Categorization
Characteristics < 5% (n = 58, 696) 5%-10% (n = 10, 037) ≥ 10% (n = 3, 395) Risk factors used in equation Age, y 47.3 ± 8.2 59.5 ± 7.2 63.3 ± 8.2 Male, n (%) 33, 089 (56.4) 9, 100 (90.7) 3, 306 (97.4) SBP (mmHg) 120.6 ± 14.8 139.1 ± 14.2 154.4 ± 16.2 TC (mmol/L) 4.81 ± 0.87 4.96 ± 0.94 5.12 ± 1.08 HDL-C (mmol/L) 1.51 ± 0.34 1.38 ± 0.31 1.32 ± 0.29 WC (cm) 79.7 ± 10.4 86.9 ± 8.3 88.7 ± 24.7 Current smoking, n (%) 10, 847 (18.5) 3, 969 (39.5)* 1, 365 (40.2)* Diabetes mellitus, n (%) 2, 266 (3.9) 2, 458 (24.5) 1, 799 (53.0) Hypertension treatment, n (%) 2, 959 (5.0) 3, 765 (37.5) 2, 096 (61.7) Urban, n (%) 57, 193 (97.4) 9, 514 (94.7) 3, 027 (89.2) Southern China, n (%) 58, 696 (100) 10, 037 (100) 3, 395 (100) Family history of ASCVD, n (%) 2, 483 (4.2) 1, 214 (12.1)* 437 (12.9)* Risk factors not used in equation BMI (kg/m2) 23.7 ± 3.0 25.6 ± 3.1* 25.9 ± 3.1* WHR 0.84 ± 0.08 0.91 ± 0.05 0.93 ± 0.25 WHtR 0.48 ± 0.05 0.51 ± 0.04 0.53 ± 0.15 DBP (mmHg) 75.2 ± 10.7 85.3 ± 10.8 89.7 ± 12.5 UA (μmol/L) 336.1 ± 87.1 381.8 ± 82.4 384.4 ± 85.3 FPG (mmol/L) 5.64 ± 0.94 6.51 ± 1.74 7.49 ± 2.35 TG (mmol/L) 1.51 ± 1.14 2.01 ± 1.63 2.41 ± 2.37 LDL-C (mmol/L) 2.71 ± 0.74 2.78 ± 0.81 2.83 ± 0.88 Non-HDL-C (mmol/L) 3.31 ± 0.87 3.58 ± 0.93 3.8 ± 1.09 TC/HDL-C 3.33 ± 0.88 3.72 ± 0.99 4.05 ± 1.42 ALT (U/L) 26.9 ± 20.1 29.9 ± 19.8 30.6 ± 19.5 AST (U/L) 21.8 ± 10.5 23.7 ± 10.8* 24.3 ± 10.2* ALP (U/L) 64.7 ± 18.4 70.1 ± 19.0 72.0 ± 20.4 Note.*Asterisk represents no statistical difference between the two groups. ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; WHtR, waist height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; UA, plasma uric acid; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, calculated as TC- HDL-C; TC/HDL-C, calculated as TC divided by the HDL-C; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase. The characteristics of CVD risk factors are shown in Table 2. The proportion of overweight/ obesity and metabolic abnormalities in both 10-year CVD risk categorizations were compared using a chi-square test. The results show that the intermediate/high-risk group has a higher proportion of individuals with general and abdominal overweight/obesity classifications, hypertension, hyperuricemia, and glycolipid abnormalities.
Table 2. The Proportion of Overweight/obesity and Metabolic Abnormalities in the Two 10-year CVD Risk Categorization
aParameters < 5% (n = 58, 696) ≥ 5% (n = 13, 432) Overweight/obesity, n(%) BMI ≥ 24 kg/m2 45.0% 71.3% WC ≥ 85/80 cm 17.2% 40.2% WHR ≥ 0.9/0.85 30.3% 61.3% WHtR ≥ 0.5 34.6% 66.7% Hypertension, n(%) SBP ≥ 140 mmHg 9.9% 55.4% DBP ≥ 90 mmHg 9.4% 38.0% Abnormal glucose metabolism, n(%) FPG ≥ 6.1 mmol/L 15.6% 51.8% Dyslipidemia, n(%) TC ≥ 5.2 mmol/L 30.0% 38.7% TG ≥ 1.7 mmol/L 28.1% 46.9% HDL-C < 1.0 mmol/L 1.7% 4.5% LDL-C ≥ 3.4 mmol/L 16.5% 21.9% Non-HDL-C ≥ 4.1 mmol/L 17.0% 27.6% TC/HDL-C ≥ 5.0 3.7% 9.4% Hyperuricemia, n(%) UA ≥ 420/350 μmol/L 18.4% 30.0% Note. BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist to hip ratio; WHtR, waist height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; UA, plasma uric acid; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, calculated as TC-HDL-C; TC/HDL-C, calculated as TC divided by the HDL-C; WC ≥ 85 cm in men and ≥ 80 cm in women; WHR ≥ 0.9 in men and ≥ 0.85 in women; UA ≥ 420 μmol/L in men and postmenopausal women, and ≥ 350 μmol/L in premenopausal women. -
Univariate regression analysis showed that all risk factors, whether or not components of the China-PAR equation, were significantly associated with 10-year CVD risk. However, the adjusted OR of WC decreased to 0.91 (CI 95% = 0.83-1.00) when analyzed together with other variables (P = 0.049). Similarly, BMI was no longer associated with intermediate or high CVD risk (P = 0.057) after further adjustment for other CVD risk factors. The adjusted OR of both WHR and WHtR was 1.16 with statistically significant differences in P-values when multiple regression analysis was performed (Table 3).
Table 3. Simple and Multiple Regression Analysis of Risk Factors for 10-year ASCVD Risk
Variables Simple Logistic Regression Analysis Multiple Logistic Regression Analysis β Unadjusted OR (95% CI) P Values β Adjusted OR (95% CI) P Values Risk factors used in equation Age 2.457 11.67 (11.08-12.28) < 0.001 3.670 39.26 (35.73-43.14) < 0.001 Female -2.236 0.10 (0.10-0.11) < 0.001 -4.204 0.01 (0.01-0.01) < 0.001 SBP 2.420 11.24 (10.76-11.74) < 0.001 2.574 13.12 (12.06-14.27) < 0.001 TC 0.389 1.47 (1.42-1.53) < 0.001 0.119 1.12 (1.01-1.24) 0.021 HDL-C 1.012 2.75 (2.48-3.05) < 0.001 0.512 1.66 (1.38-2.01) < 0.001 WC 1.171 3.22 (3.09-3.35) < 0.001 -0.093 0.91 (0.83-1.00) 0.049 Current smoking 1.067 2.90 (2.79-3.02) < 0.001 0.650 1.91 (1.78-2.05) < 0.001 Diabetes 2.447 11.55 (10.93-12.21) < 0.001 2.108 8.23 (7.41-9.13) < 0.001 Hypertension treatment 2.680 14.58 (13.86-15.33) < 0.001 2.358 10.57 (9.74-11.46) < 0.001 Family history of ASCVD 1.155 3.17 (2.97-3.38) < 0.001 0.606 1.83 (1.62-2.06) < 0.001 Risk factors not used in equation BMI 1.109 3.03 (2.90-3.15) < 0.001 -0.084 0.91 (0.84-1.00) 0.057 WHR 1.294 3.64 (3.50-3.79) < 0.001 0.149 1.16 (1.06-1.26) < 0.001 WHtR 1.328 3.77 (3.62-3.92) < 0.001 0.151 1.16 (1.05-1.28) 0.002 DBP 1.772 5.88 (5.62-6.15) < 0.001 0.542 1.72 (1.58-1.86) < 0.001 UA 0.645 1.90 (1.82-1.98) < 0.001 -0.030 0.97 (0.90-1.04) 0.427 FPG 1.760 5.81 (5.58-6.05) < 0.001 0.375 1.45 (1.34-1.57) < 0.001 TG 0.815 2.25 (2.17-2.34) < 0.001 0.066 1.06 (0.99-1.14) 0.069 LDLc 0.353 1.42 (1.35-1.49) < 0.001 0.226 1.25 (1.13-1.38) < 0.001 Non-HDL-C 0.618 1.85 (1.77-1.93) < 0.001 0.211 1.23 (1.09-1.39) 0.001 TC/HDL-C 0.994 2.70 (2.51-2.90) < 0.001 0.523 1.68 (1.46-1.94) < 0.001 Note. OR, Odds ratio; CI, confidence interval; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; WHtR, waist height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; UA, plasma uric acid; FPG, fasting plasma glucose; TC, total cholesterol; triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, calculated as TC-HDL-C; TC/HDL-C, calculated as TC divided by the HDL-C. The adjusted ORs of TC and HDL-C were 1.12 (CI 95% = 1.01-1.24) and 1.66 (CI 95% = 1.38-2.01), and the adjusted ORs of LDL-C, non-HDL-C, and TC/HDL-C were 1.25 (CI 95% = 1.13-1.38), 1.23 (CI 95% = 1.09-1.39), and 1.68 (CI 95% = 1.46-1.94), respectively, which are all higher than that of TC. FPG and DBP were significantly associated with CVD risk with adjusted ORs of 1.45 (CI 95% = 1.34-1.57) and 1.72 (CI 95% = 1.58-1.86), respectively. The risk factors of UA and TG were excluded from the binary logistic regression model when analyzed together with other variables (P-values were 0.427 and 0.069, respectively) (Table 3).
doi: 10.3967/bes2019.014
Applying the China-PAR Risk Algorithm to Assess 10-year Atherosclerotic Cardiovascular Disease Risk in Populations Receiving Routine Physical Examinations in Eastern China
-
Abstract:
Objective To assess the 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk score among adults in eastern China using the China-PAR equation which formulated primarily for the Chinese population. Methods Data from 72, 129 individuals from 35-74 years old who received routine physical examinations in eastern China were analyzed in this study. The 10-year risk scores were calculated using the China-PAR equation. The chi-square test and logistic regression were then performed to evaluate the association between the selected risk factors and overall CVD risk. Results The mean 10-year ASCVD risk scores were 3.82% ±3.76% in men and 1.30% ±1.65% in women based on the China-PAR equation. Overall, 20% of men and 3.5% of women were intermediate-risk, and 7.3% of men and 0.3% of women were high-risk. Waist to hip ratio (WHR)[OR=1.16 (CI 95%=1.06-1.26)], waist to height ratio (WHtR)[OR=1.16 (CI 95%=1.05-1.28)], non-high-density lipoprotein cholesterol (non-HDL-C)[OR=1.23 (CI 95%=1.09-1.39)], and total cholesterol (TC)/HDL-C[OR=1.68 (CI 95%=1.46-1.94)] were more strongly associated with CVD risk than body-mass index (BMI), waist circumference (WC), and TC alone. Conclusion Male-specific prevention and treatment strategies for ASCVD are needed in eastern China. In addition, WHR, WHtR, non-HDL-C, and TC/HDL-C which not included in the the China-PAR equation were also independently associated with 10-year ASCVD risk score categories. -
Key words:
- Cardiovascular disease /
- Cardiovascular risk score /
- China-PAR equation /
- Risk factors
-
Table 1. The Value of Risk Factors in the Three 10-year ASCVD Risk Categorization
Characteristics < 5% (n = 58, 696) 5%-10% (n = 10, 037) ≥ 10% (n = 3, 395) Risk factors used in equation Age, y 47.3 ± 8.2 59.5 ± 7.2 63.3 ± 8.2 Male, n (%) 33, 089 (56.4) 9, 100 (90.7) 3, 306 (97.4) SBP (mmHg) 120.6 ± 14.8 139.1 ± 14.2 154.4 ± 16.2 TC (mmol/L) 4.81 ± 0.87 4.96 ± 0.94 5.12 ± 1.08 HDL-C (mmol/L) 1.51 ± 0.34 1.38 ± 0.31 1.32 ± 0.29 WC (cm) 79.7 ± 10.4 86.9 ± 8.3 88.7 ± 24.7 Current smoking, n (%) 10, 847 (18.5) 3, 969 (39.5)* 1, 365 (40.2)* Diabetes mellitus, n (%) 2, 266 (3.9) 2, 458 (24.5) 1, 799 (53.0) Hypertension treatment, n (%) 2, 959 (5.0) 3, 765 (37.5) 2, 096 (61.7) Urban, n (%) 57, 193 (97.4) 9, 514 (94.7) 3, 027 (89.2) Southern China, n (%) 58, 696 (100) 10, 037 (100) 3, 395 (100) Family history of ASCVD, n (%) 2, 483 (4.2) 1, 214 (12.1)* 437 (12.9)* Risk factors not used in equation BMI (kg/m2) 23.7 ± 3.0 25.6 ± 3.1* 25.9 ± 3.1* WHR 0.84 ± 0.08 0.91 ± 0.05 0.93 ± 0.25 WHtR 0.48 ± 0.05 0.51 ± 0.04 0.53 ± 0.15 DBP (mmHg) 75.2 ± 10.7 85.3 ± 10.8 89.7 ± 12.5 UA (μmol/L) 336.1 ± 87.1 381.8 ± 82.4 384.4 ± 85.3 FPG (mmol/L) 5.64 ± 0.94 6.51 ± 1.74 7.49 ± 2.35 TG (mmol/L) 1.51 ± 1.14 2.01 ± 1.63 2.41 ± 2.37 LDL-C (mmol/L) 2.71 ± 0.74 2.78 ± 0.81 2.83 ± 0.88 Non-HDL-C (mmol/L) 3.31 ± 0.87 3.58 ± 0.93 3.8 ± 1.09 TC/HDL-C 3.33 ± 0.88 3.72 ± 0.99 4.05 ± 1.42 ALT (U/L) 26.9 ± 20.1 29.9 ± 19.8 30.6 ± 19.5 AST (U/L) 21.8 ± 10.5 23.7 ± 10.8* 24.3 ± 10.2* ALP (U/L) 64.7 ± 18.4 70.1 ± 19.0 72.0 ± 20.4 Note.*Asterisk represents no statistical difference between the two groups. ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; WHtR, waist height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; UA, plasma uric acid; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, calculated as TC- HDL-C; TC/HDL-C, calculated as TC divided by the HDL-C; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase. Table 2. The Proportion of Overweight/obesity and Metabolic Abnormalities in the Two 10-year CVD Risk Categorization
aParameters < 5% (n = 58, 696) ≥ 5% (n = 13, 432) Overweight/obesity, n(%) BMI ≥ 24 kg/m2 45.0% 71.3% WC ≥ 85/80 cm 17.2% 40.2% WHR ≥ 0.9/0.85 30.3% 61.3% WHtR ≥ 0.5 34.6% 66.7% Hypertension, n(%) SBP ≥ 140 mmHg 9.9% 55.4% DBP ≥ 90 mmHg 9.4% 38.0% Abnormal glucose metabolism, n(%) FPG ≥ 6.1 mmol/L 15.6% 51.8% Dyslipidemia, n(%) TC ≥ 5.2 mmol/L 30.0% 38.7% TG ≥ 1.7 mmol/L 28.1% 46.9% HDL-C < 1.0 mmol/L 1.7% 4.5% LDL-C ≥ 3.4 mmol/L 16.5% 21.9% Non-HDL-C ≥ 4.1 mmol/L 17.0% 27.6% TC/HDL-C ≥ 5.0 3.7% 9.4% Hyperuricemia, n(%) UA ≥ 420/350 μmol/L 18.4% 30.0% Note. BMI, body mass index; WC, waist circumference; HC, hip circumference; WHR, waist to hip ratio; WHtR, waist height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; UA, plasma uric acid; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, calculated as TC-HDL-C; TC/HDL-C, calculated as TC divided by the HDL-C; WC ≥ 85 cm in men and ≥ 80 cm in women; WHR ≥ 0.9 in men and ≥ 0.85 in women; UA ≥ 420 μmol/L in men and postmenopausal women, and ≥ 350 μmol/L in premenopausal women. Table 3. Simple and Multiple Regression Analysis of Risk Factors for 10-year ASCVD Risk
Variables Simple Logistic Regression Analysis Multiple Logistic Regression Analysis β Unadjusted OR (95% CI) P Values β Adjusted OR (95% CI) P Values Risk factors used in equation Age 2.457 11.67 (11.08-12.28) < 0.001 3.670 39.26 (35.73-43.14) < 0.001 Female -2.236 0.10 (0.10-0.11) < 0.001 -4.204 0.01 (0.01-0.01) < 0.001 SBP 2.420 11.24 (10.76-11.74) < 0.001 2.574 13.12 (12.06-14.27) < 0.001 TC 0.389 1.47 (1.42-1.53) < 0.001 0.119 1.12 (1.01-1.24) 0.021 HDL-C 1.012 2.75 (2.48-3.05) < 0.001 0.512 1.66 (1.38-2.01) < 0.001 WC 1.171 3.22 (3.09-3.35) < 0.001 -0.093 0.91 (0.83-1.00) 0.049 Current smoking 1.067 2.90 (2.79-3.02) < 0.001 0.650 1.91 (1.78-2.05) < 0.001 Diabetes 2.447 11.55 (10.93-12.21) < 0.001 2.108 8.23 (7.41-9.13) < 0.001 Hypertension treatment 2.680 14.58 (13.86-15.33) < 0.001 2.358 10.57 (9.74-11.46) < 0.001 Family history of ASCVD 1.155 3.17 (2.97-3.38) < 0.001 0.606 1.83 (1.62-2.06) < 0.001 Risk factors not used in equation BMI 1.109 3.03 (2.90-3.15) < 0.001 -0.084 0.91 (0.84-1.00) 0.057 WHR 1.294 3.64 (3.50-3.79) < 0.001 0.149 1.16 (1.06-1.26) < 0.001 WHtR 1.328 3.77 (3.62-3.92) < 0.001 0.151 1.16 (1.05-1.28) 0.002 DBP 1.772 5.88 (5.62-6.15) < 0.001 0.542 1.72 (1.58-1.86) < 0.001 UA 0.645 1.90 (1.82-1.98) < 0.001 -0.030 0.97 (0.90-1.04) 0.427 FPG 1.760 5.81 (5.58-6.05) < 0.001 0.375 1.45 (1.34-1.57) < 0.001 TG 0.815 2.25 (2.17-2.34) < 0.001 0.066 1.06 (0.99-1.14) 0.069 LDLc 0.353 1.42 (1.35-1.49) < 0.001 0.226 1.25 (1.13-1.38) < 0.001 Non-HDL-C 0.618 1.85 (1.77-1.93) < 0.001 0.211 1.23 (1.09-1.39) 0.001 TC/HDL-C 0.994 2.70 (2.51-2.90) < 0.001 0.523 1.68 (1.46-1.94) < 0.001 Note. OR, Odds ratio; CI, confidence interval; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; WHtR, waist height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; UA, plasma uric acid; FPG, fasting plasma glucose; TC, total cholesterol; triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, calculated as TC-HDL-C; TC/HDL-C, calculated as TC divided by the HDL-C. -
[1] Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis, 1967; 20, 511-24. doi: 10.1016/0021-9681(67)90082-3 [2] Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63, 2935-59. doi: 10.1016/j.jacc.2013.11.005 [3] Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA, 2004; 291, 2591-9. doi: 10.1001/jama.291.21.2591 [4] Yang X, Li J, Hu D, et al. Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population:The China-PAR Project (Prediction for ASCVD Risk in China). Circulation, 2016; 134, 1430-40. doi: 10.1161/CIRCULATIONAHA.116.022367 [5] Zhang M, Jiang Y, Wang LM, et al. Prediction of 10-year Atherosclerotic Cardiovascular Disease Risk among Adults Aged 40-79 Years in China:a Nationally Representative Survey. Biomed Environ Sci, 2017; 30, 244-54. [6] WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet, 2004; 363, 157-63. doi: 10.1016/S0140-6736(03)15268-3 [7] American Diabetes Association. Standards of Medical Care in Diabetes-2018. Diabetes Care, 2018; 41, S144-51. doi: 10.2337/dc18-S014 [8] Liu XZ, Gao Y, Fan J, et al. Metabolic abnormalities in rheumatoid arthritis patients with comorbid diabetes mellitus. Clin Rheumatol, 2018; 37, 219-26. doi: 10.1007/s10067-017-3847-7 [9] Li HH, Fan J, Huang S, et al. The prevalence of obesity and metabolic abnormalities in eastern China: A cross-sectional study. Int J Diabetes Dev Ctries, 2019 Feb 20.[Epub ahead of print] [10] Johansson HE, Wåhlén A, Aldenbäck E, et al. Platelet Counts and Liver Enzymes After Gastric Bypass Surgery. Obes Surg, 2018; 28, 1526-31. doi: 10.1007/s11695-017-3035-5 [11] Guerra-Silva NM, Santucci FS, Moreira RC, et al. Coronary disease risk assessment in men:Comparison between ASCVD Risk versus Framingham. Int J Cardiol, 2017; 228, 481-7. doi: 10.1016/j.ijcard.2016.11.102 [12] Yang XL, Chen JC, Li JX, et al. Risk stratification of atherosclerotic cardiovascular disease in Chinese adults. Chronic Dis Transl Med, 2016; 2, 102-9. doi: 10.1016/j.cdtm.2016.10.001 [13] Winham SJ, de Andrade M, Miller VM. Genetics of cardiovascular disease:Importance of sex and ethnicity. Atherosclerosis, 2015; 241, 219-28. doi: 10.1016/j.atherosclerosis.2015.03.021 [14] Sun C, Xu F, Liu X, et al. Comparison of validation and application on various cardiovascular disease mortality risk prediction models in Chinese rural population. Sci Rep, 2017; 7, 43227. doi: 10.1038/srep43227 [15] Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol, 2018; 14, 185-201. http://www.nature.com/articles/nrneph.2017.189 [16] Bray GA, Smith SR, de Jonge L, et al. Effect of dietary protein content on weight gain, energy expenditure, and body composition during overeating:a randomized controlled trial. JAMA, 2012; 307, 47-55. doi: 10.1001/jama.2011.1918 [17] Paniagua L, Lohsoonthorn V, Lertmaharit S, et al. Comparison of waist circumference, body mass index, percent body fat and other measure of adiposity in identifying cardiovascular disease risks among Thai adults. Obes Res Clin Pract, 2008; 2, I-Ⅱ. doi: 10.1016/S1871-403X(08)00009-4 [18] Ouyang X, Lou Q, Gu L, et al. Anthropometric parameters and their associations with cardio-metabolic risk in Chinese working population. Diabetol Metab Syndr, 2015; 7, 37. doi: 10.1186/s13098-015-0032-5 [19] Schneider HJ, Glaesmer H, Klotsche J, et al. Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. J Clin Endocrinol Metab, 2007; 92, 589-94. doi: 10.1210/jc.2006-0254 [20] Caan B, Armstrong MA, Selby JV, et al. Changes in measurements of body fat distribution accompanying weight change. Int J Obes Relat Metab Disord, 1994; 18, 397-404. http://eurheartj.oxfordjournals.org/lookup/external-ref?access_num=8081431&link_type=MED&atom=%2Fehj%2F28%2F7%2F850.atom [21] Shao J, Yu L, Shen X, et al. Waist-to-height ratio, an optimal predictor for obesity and metabolic syndrome in Chinese adults. J Nutr Health Aging, 2010; 14, 782-5. doi: 10.1007/s12603-010-0106-x [22] Ashwell M, Gibson S. Waist to height ratio is a simple and effective obesity screening tool for cardiovascular risk factors:Analysis of data from the British National Diet And Nutrition Survey of adults aged 19-64 years. Obes Facts, 2009; 2, 97-103. doi: 10.1159/000203363 [23] Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors:systematic review and meta-analysis. Obes Rev, 2012; 13, 275-86. doi: 10.1111/j.1467-789X.2011.00952.x [24] Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes:0.5 could be a suitable global boundary value. Nutr Res Rev, 2010; 23, 247-69. doi: 10.1017/S0954422410000144 [25] Parish S, Offer A, Clarke R, et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation, 2012; 125, 2469-78. doi: 10.1161/CIRCULATIONAHA.111.073684 [26] Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease:10, 158 incident cases among 262, 525 participants in 29 Western prospective studies. Circulation, 2007; 115, 450-8. doi: 10.1161/CIRCULATIONAHA.106.637793 [27] Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007; 298, 309-16. doi: 10.1001/jama.298.3.309 [28] Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes:a systematic review and meta-analysis. Lancet, 2010; 375, 1875-84. doi: 10.1016/S0140-6736(10)60656-3 [29] Würtz P, Kangas A, Soininen P, et al. Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease:a note on Mendelian randomization studies. J Am Coll Cardiol, 2013; 62, 1906-8. doi: 10.1016/j.jacc.2013.07.085 [30] Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA, 2005; 294, 326-33. doi: 10.1001/jama.294.3.326 [31] Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016; 37, 2999-3058. doi: 10.1093/eurheartj/ehw272 [32] McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study):a case-control study. Lancet, 2008; 372, 224-33. doi: 10.1016/S0140-6736(08)61076-4 [33] Elshazly MB, Quispe R, Michos ED, et al. Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol:The Very Large Database of Lipids Study (VLDL-2B). Circulation, 2015; 132, 667-76. doi: 10.1161/CIRCULATIONAHA.115.016163 [34] Borghi C, Rodriguez-Artalejo F, De Backer G, et al. Serum uric acid levels are associated with cardiovascular risk score:A post hoc analysis of the EURIKA study. Int J Cardiol, 2018; 253, 167-73. doi: 10.1016/j.ijcard.2017.10.045 [35] Li X, Meng X, Timofeeva M, et al. Serum uric acid levels and multiple health outcomes:umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ, 2017; 357, j2376. http://www.bmj.com/content/357/bmj.j2376 [36] Liu XZ, Li HH, Huang S, et al. Association between hyperuricemia and nontraditional adiposity indices. Clin Rheumatol, 2018 Nov 29.[Epub ahead of print] [37] Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta, 2018; 484, 150-63. doi: 10.1016/j.cca.2018.05.046